Latest news articles

Added 5 months ago Drug news

PROLONG trial evaluating Makena did not meet endpoint in preterm delivery

AMAG Pharmaceuticals announced topline results from PROLONG, a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena (progestin) in patients with a...

Added 1 year ago Drug news

FDA approves PartoSure diagnostic to assess risk of spontaneous preterm birth.- Qiagen.

Qiagen announced the U.S. regulatory approval of PartoSure, which is a novel test for assessing the risk of spontaneous preterm...

Added 3 years ago Drug news

FDA approves aingle dose formulation of Makena (hydroxyprogesterone caproate injection) for preterm labour -AMAG Pharmaceuticals

The FDA has approved a single-dose, preservative-free formulation of Makena (hydroxyprogesterone caproate injection) from AMAG Pharmaceuticals. Makena is the only...

Search all news articles for Early or threatened labour

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more



See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more


Preterm labour and birth

This guideline covers the care of women at increased risk of or with symptoms and signs of preterm labour (before 37 weeks) and women having a planned preterm birth.

Added 3 years ago

Search all guidelines for Early or threatened labour

Journal articles

Oxytocin, its antagonist Atosiban, and preterm labor: a role for placental nitric oxide.

Objective: The aim of the present study was to understand the role played by Atosiban, an oxytocin receptor antagonist, on...

Added 4 years ago

Search all journal articles for Early or threatened labour